Abstract
Combination therapy is a common approach in the treatment of acne vulgaris to simultaneously target the multiple pathogenic factors. The use of a topical retinoid in conjunction with an antimicrobial agent is a standard-of-care for most cases of acne. Recently, adapalene 0.1% and benzoyl peroxide 2.5% fixed-dose combination gel was approved for the treatment of acne vulgaris. Results from clinical trials provide robust evidence that this fixed-dose combination gel is significantly more efficacious than its corresponding monotherapies and has a mild tolerability profile similar to that of adapalene alone.
Financial & competing interests disclosure
Editorial and medical writing support was provided by Galderma Laboratories L.P. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Writing assistance was utilized in the production of this manuscript and funded by Galderma Laboratories L.P.